Register
Login:
Share:
Email Facebook Twitter


Market analyst Rajan Dhall talks about the financial market


Immupharma Share Price (IMM)



Share Price Information for Immupharma (IMM)


Share Price: 53.00Bid: 52.75Ask: 53.00Change: 0.00 (0.00%)No Movement on Immupharma
Spread: 0.25Spread as %: 0.47%Open: 52.00High: 53.00Low: 51.25Yesterday’s Close: 53.00

Immupharma Plc Ord 10P

Immupharma is listed in the FTSE AIM All-Share
Immupharma is part of the Medicine and Biotech Research sector






Share Price SpacerPrice
53.00

Share Price SpacerBid
52.75

Share Price SpacerAsk
53.00

Share Price SpacerChange
0%0.00

Share Price SpacerVolume
203,624

Share Price SpacerOpen
52.00

Share Price SpacerHigh
53.00

Share Price SpacerLow
51.25

Share Price SpacerClose
53.00

Share Price SpacerCurrency
GBX


Currency Issue Country Shares in Issue Market Capitalisation Market Size
GBX GB 132.52m £70.24m 5,000

52 Week High 69.00 52 Week High Date 17-FEB-2017
52 Week Low 33.00 52 Week Low Date 9-NOV-2016

# Trades Vol. Sold Vol. Bought PE Ratio Earnings Dividend Yield
24 83,738 119,886 -11.674 -4.54 0.00 0.00


London South East Users info for Immupharma




Date
Time
Trade Prc
Volume
Buy/Sell
Bid
Ask
Value
 

27-Jun-17
15:43:33
52.20
50,000
Sell* 
52.75
53.00
26.10k
Trade Type:
Ordinary

27-Jun-17
17:08:40
53.00
10,000
Buy* 
52.75
53.00
5,300
Trade Type:
Ordinary

27-Jun-17
16:53:52
51.25
655
Sell* 
52.75
53.00
335.69
Trade Type:
Ordinary
Bargain conditions apply




View more Immupharma trades >>

Directors Deals for Immupharma (IMM)
Trade DateActionNotifierPriceCurrencyAmountHolding
30-Apr-15Notification of Holding
Trade Notifier Information for Immupharma
Stephane Robert George Mery held the position of Non-Executive Director at Immupharma at the time of this trade.
 Stephane Robert George Mery
002259
24-Jan-13Sell
Trade Notifier Information for Immupharma
Ajay Agrawal held the position of Non-Executive Director at Immupharma at the time of this trade.
 Ajay Agrawal
57GBX62,1690
24-Jan-12Buy
Trade Notifier Information for Immupharma
Ajay Agrawal held the position of Non-Executive Director at Immupharma at the time of this trade.
 Ajay Agrawal
80GBX62,1690
View more Immupharma directors dealings >>



Date/TimeAuthorSubjectShare PriceOpinion
Sun 13:05boomorbustRE: 2014 RNS - "Potential Partner"52.375No Opinion
Think he was referring to the partnership with Simbec-Orion. The RNS is dated October 2014 and states:-

"Following advanced discussions and after completing detailed due diligence with a potential partner, ImmuPharma has started the preparatory steps for Lupuzor’s™ pivotal phase III clinical trials. Before these initial activities are completed, it is expected that a further agreement to develop Lupuzor™ will be finalised and signed which will see Immupharma and the… Read More
Sun 12:06leasRE: 2014 RNS - "Potential Partner"52.375No Opinion
Hi Rocky, I think the company was exploring their options on how to take Lupuzor into p3 trials. At the time they did not have the funding but employed the services of Torreya to negotiate on their behalf. Thankfully that did not happen.
Make no mistake, IMM have a strong hand here and so far they do not give the impression that they are 'going to give away any rights' on the cheap.
All of course depends on a successful trial, but remembering that there are other compounds in development.
Sun 00:50Rocky882014 RNS - "Potential Partner"52.375No Opinion
Reading back to 2014 I find there was reference to a potential partner...

"Dr Robert Zimmer, ImmuPharma's President and Chief Scientific Officer, further commented: "The entry of Lupuzor™ into pivotal Phase III trials involves a potential partner with strong credentials and expertise in late stage clinical development. Furthermore they provide an independent validation of Lupuzor's™ potential to become a leading treatment for lupus patients world-wide"

Does… Read More
Thu 19:20westie50RE: A reminder of the potential here51.875No Opinion
Excellent post oilbagger. Reminds us all why we're here. Long term hold I think. Nothing is going to happen quickly. I'm looking at next year personally.
20 Jun '17oilbaggerA reminder of the potential here52.00Strong Buy
I had another play of this old video from June 2016 of Sylvaine Muller that highlights the potential of the drug platform that Lupuzor is based. The potential is enormous so worth looking at again to remind yourself of the potential here beyond the treatment of Lupus

Sylvaine Muller, creator of ImmuPharma PLC’s (LON:IMM) lead drug candidate Lupuzor, tells Proactive Investors the treatment is “unique” in its treatment for auto-immune disease lupus, as it only targets only… Read More
20 Jun '17oilbaggerspread is tight52.00Strong Buy
The spread is tight at the minute 52.36 to buy and can sell 50k share in at 52.125p
Looks like they are keen to mop up any shares - they aren't having mine !!
Happy to wait.

Share prices shown are taken at time of message posting.
Thread ViewThread View
View more share chat for Immupharma (IMM) >>

Please login or register to post a message on Share Chat.








Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk








Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.